This webinar will see an expert panel discuss the joint ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer.
ERS in close collaboration with ESTS/ESTI, ESTS, ESTRO and EFOMP has recently published 2 Taskforce reports on incidental findings and high-quality standards in LDCT lung cancer programs. Both first authors will present and interactively discuss the key topics of these two European multi-society-driven Taskforce reports. Broad pan-European implementation of these valuable Taskforce reports will help to better tailor LDCT lung cancer screening programs on the national level as well as to increase their efficacy and reduce their potential harms.
Educational aims
Participants of this webinar-to learn about the practical applications and the added-value of the 2 multi-disciplinary European Taskforce reports on incidental findings as well as standards for high-quality programs in LDCT lung cancer screening published by ERS, ESR/ESTI, ESTS, ESTRO, and EFOMP.
Topics
1) Introduction to webinar: DRB
2) ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer:
- Purpose and methods DRB
- Respiratory recommendations with key points for discussion EOD – presentation/discussion
- Cardiovascular recommendations DRB – presentation/discussion
- Other common findings and recommendations EOD. – presentation/discussion
3) Developing a Pan-European Technical Standard for a Comprehensive High-quality Lung Cancer CT Screening Program. An ERS Technical Standard
- Topics covered DRB
- Selected challenging topics. EOD and DRB – presentation/discussion
4) Conclusions and Outlook: DRB and EOD
Target audience
- Pulmonulogists
- Radiologists
- Thoracic Surgeons
- Radiotherapists, Medical Oncologists
- Oncologists
- Epidemiologists
- General Practitioners
- (Lung Cancer) Nurses
- Lung Cancer Screening Program Managers
Format
This webinar will include brief presentations of core topics, followed by interactive panel discussion.
Learning outcomes
- Better appraise incidental findings deriving from LDCT lung cancer screening, categorize these according to their clinical impact as well to report/avoid reporting these
- Better understand the complexity and interplay within a comprehensive, high-quality LDCT lung cancer screening program
CME credit
An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only.
What is a webinar?
A webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting. During the webinar, you will be asked to share your opinion on issues related to the topic using interactive polls.
All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.
Login guidelines
More information will be communicated in due course.
- Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact e-learning@ersnet.org.
- Check Central European Time.
- To achieve the best quality, we recommend to avoid downloading anything from the internet during your connection to the lecture and stopping all other programmes.
- Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.
Target audience
- Pulmonologists
- Radiologists
- Thoracic surgeons
- Radiotherapists
- Medical oncologists
- Oncologists
- Epidemiologists
- General practitioners
- Lung cancer nurses
- Lung cancer screening program managers